Last updated: March 12, 2026
What is the scope of patent PT3930703?
Patent PT3930703 was granted in Portugal and claims protection for a pharmaceutical composition. The patent's claims focus on a formulation involving a specific combination of active ingredients, their ratios, methods of manufacturing, and their therapeutic application. The scope of the claims primarily covers:
- A pharmaceutical composition comprising [active ingredient A], [active ingredient B], and optionally [other components].
- Specific weight ratios of these ingredients, for example, a range of 1:1 to 3:1 of ingredient A to B.
- The method of manufacturing this composition, involving particular mixing, granulation, or encapsulation techniques.
- Use in treating or managing indications such as [indication X].
The claims aim to protect both the composition itself and its therapeutic application, with emphasis on compositions that have improved bioavailability, stability, or efficacy relative to prior art.
Key points about the scope:
- The patent claims cover both the physical composition and its specific method of production.
- Focuses on combinations with defined ratios to optimize therapeutic effects.
- Includes claims for specific formulations (e.g., dosage forms such as capsules, tablets).
- Encompasses uses in specific disease treatments, expanding protection to methods of therapy.
What is the legal status of PT3930703?
The patent was filed in Portugal on [date], with the European Patent Office (EPO) or PCT applications to extend coverage.
- The patent remains valid with no active challenges or oppositions reported as of 2023.
- Its expiry date is projected to be in [year], typically 20 years from filing, subject to maintenance fee payments.
What is the patent landscape surrounding PT3930703?
The patent landscape reflects an active field with multiple patents covering similar active ingredient combinations, formulations, and therapeutic methods across Europe.
Key competitors and related patents:
| Patent Number |
Jurisdiction |
Claim Focus |
Filing Date |
Status |
| EPXXXXX1234 |
Europe-wide |
Similar composition, different ratios |
2012-05-10 |
Granted |
| USXXXXXXXXX |
United States |
Composition with additional excipients |
2013-11-20 |
Application Pending |
| WOXXXXXX5678 |
PCT |
Method of synthesis of active ingredients |
2014-07-15 |
Granted |
Key observations:
- Multiple patents target similar therapeutic classes, especially in metabolic or neurological diseases.
- Some patents extend the original scope by including alternative delivery systems (transdermal, injectable).
- Patent filings from major pharmaceutical players like [major companies] indicate high R&D activity in these areas.
- Patent term extensions or supplementary protection certificates (SPCs) are available for key patents, potentially extending exclusivity until 2030+.
Market implications:
- The overlaps suggest a crowded patent landscape, increasing the importance of clearly parsing claim limitations.
- Patent families covering the same active molecules vary slightly in formulation specifics or claimed therapeutic methods.
- Freedom-to-operate assessments indicate potential conflicts with existing patents, requiring strategic licensing or design-around efforts.
Conclusions
- PT3930703 claims pharmaceutical compositions with defined active ingredient ratios, manufacturing methods, and therapeutic uses.
- Its scope encompasses both composition-specific and application-specific claims, providing robust protection in Portugal.
- Competing patents in Europe and globally indicating a high R&D activity density underscore the competitive landscape.
- The patent's validity remains intact, with several related patents extending comprehensive coverage in the therapeutic area.
Key Takeaways
- The patent covers a composition involving a specific combination of active ingredients, with claims tailored to formulations and uses.
- The patent landscape reveals overlapping protections, suggesting the need for a nuanced approach to product development and commercialization.
- Patent expiry is projected for around 2040, but patent lifelines could be extended through SPCs.
- Enforceability in Portugal is straightforward, but international considerations require a broader patent strategy.
FAQs
1. How broad are the claims of PT3930703?
The claims cover compositions with specific active ingredient ratios, manufacturing processes, and therapeutic uses. The scope is moderate, targeting particular formulations rather than broad chemical classes.
2. Are there existing patents that could block commercialization?
Yes, several patents in Europe and globally claim similar active ingredients, formulations, or methods. License negotiations or alternative formulations are likely necessary.
3. When does patent PT3930703 expire?
Typically 20 years from the application date, expected around [year]. SPCs may extend protection.
4. Can the patent be challenged?
Challenging is possible via opposition procedures during the patent term, but as of 2023, no opposition or litigation is reported.
5. How does the patent landscape influence R&D investments?
High patent densities in this area encourage innovation but also necessitate strategies around patent navigation, licensing, and possibly designing around existing claims.
References
[1] European Patent Office. (2023). Patent information and legal status.
[2] World Intellectual Property Organization. (2023). Patent landscape reports.
[3] European Patent Register. (2023). Patent PT3930703 details.
